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Two endogenous retroviral loci appear to
contribute to Multiple Sclerosis
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Abstract
Background: Two endogenous retroviral loci seem to be involved in the human disease Multiple sclerosis (MS).
Results: The two retroviral loci synergize in and contribute to MS (shown by ANOVA). Synergy probably means
recombination or complementation of the activated viruses. Similar observations may be true for Type 1 Diabetes
and Rheumatoid arthritis. In MS the genes also synergize with the immune system; this could well be a common
phenomenon.
Conclusion: We formulate various theories about the role of the viruses. Also, the concept is developing that some
forms of autoimmunity should be treatable with antiretrovirals. In the case of MS, this idea is gradually gaining
weight.
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Background
Accumulating genetic evidence as well as studies of
viral expression suggests that endogenous retroviruses
play a role in MS [1, 2]. We have shown that markers
in or near two endogenous retroviral loci, HERV-Fc1
on chromosome X and HERV-K13 on chromosome 19,
are associated with disease and synergized in influencing
the risk of MS. For synergy, we recoded the cases as 1 and
controls as 0. Then, synergy was measured as the p-value
of the product term in an ANOVA (p = 0.0009) [3]. Thus,
we measured multiplicative synergy and not simply
additivity. The odds-ratios for the double homozygotes
were OR= 0.6 for rs318138AArs2435031GG; OR = 1.3 for
rs318138GGrs2435031GG; OR = 1 for the reference geno-
type rs318138GGrs2435031TT and OR = 11 for the risk
genotype rs318138AArs2435031TT.
Also, the two viral loci synergized with a locus in the
major histocompatibility complex, MHC, known to in-
fluence MS [3](p = 0.02). The most extreme genotype
rs318138AArs2435031GTrs3135388CT had an OR = 38,
even though we applied continuity correction (i.e added
0.5 to all numbers) in order to compensate for small
numbers.
Finally, genes for three pattern recognizers for ret-
roviruses in the innate immune system, TRIM5,
TRIM22 and BST-2, influenced the risk of getting MS
[4]. Importantly, the two viral genes again synergized
with TRIM5 (Nexø BA et al, unpublished). Thus,
there is a reason to believe that the retroviral loci in-
fluence the risk of getting MS through the innate im-
mune system, and possibly also through the adaptive
immune system. The TRIM5 gene product responds
to entry of viral particles into cells. Therefore, we
have reason to believe that virus replicates in the pa-
tients at least periodically. In accordance with this,
expression of the two viruses was increased in lym-
phocytes and plasma in relation to MS [5] (Laska MJ
et al, unpublished). It must be emphasized that these
results are for the common forms of MS, relapsing/
remitting MS and secondary progressive MS, while
different mechanisms may apply to the rarer primary
progressive MS [6]. Also, bear in mind that we are
mainly studying markers on the chromosomes, and
nearby genes (< approximately 40 kb) could distort
the results. However, the presence of synergy is an ar-
gument for a role of the viral loci.
Similar, although less extensive, observations have been
made in two other autoimmune diseases: Type 1 Diabetes
(T1D) and Rheumatoid Arthritis (RA) [3]. In both diseases,
a set of retroviral loci appeared to contribute to the risk of
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disease and also synergized in this effect. Notably, a separ-
ate set of retroviral loci contributed to each of the three
diseases. MS was mentioned above. In T1D, the viruses
were HERV-K106 and HERV-K119 on chromosome 3 and
12, respectively. In RA, it was a HERV-K on chromosome
22 and a HERV-H, also on chromosome 22. In addition,
HERV-Fc1 on chromosome X seemed to contribute to RA.
All these observations were initially made in fairly focused
Scandinavian populations. However, the association of
HERV-Fc1 with MS has been repeated in two out of three
Spanish populations [7]. The population, which failed to
show the association, was the southernmost, i.e. from the
region of Spain, where non-European ethnic influences are
stronger. Thus, there may well be ethnic issues relating to
the above findings. Along the same line: In Spain, it ap-
pears that a HERV-K on chromosome 1 is associated with
MS [8]. We do not know if it replaces the one observed on
chromosome 19 in our studies of Scandinavians.
These observations may well go beyond autoimmune
diseases: We have observed a synergy of two viral loci,
HERV-Fc1 on the X chromosome and HERV-K on
chromosome 1 in the mature plasma B-cell neoplasm
Multiple Myeloma (MM) [9]. These findings could
again indicate viral recombination or complementation.
In chickens and mice, replicating retroviruses cause
leukemia by integrating into and upregulating growth
promoting regions of the chromosomes [10, 11]. It is
tempting to speculate that similar mechanisms apply in
human leukemia and autoimmunity. So maybe an im-
portant part of autoimmunity is viral lesions in and
clonal expansions of certain immune cells. Also, the oli-
goclonal IgG bands that are observed in MS intrathecal
fluid might then be explained as the result of cells with
viral lesions [12]. This represents an alternative, imme-
diately testable hypothesis for viral action in MS and
other autoimmune diseases. Under this hypothesis, we
see two possibilities: The virus activates a dormant
autoimmune cell, or it activates a primitive lymphoid
cell and develop its antigen specificity, more or less at
random. Importantly, a viral transformation of lympho-
cytes may also be tested in animal studies. Lake Casitas
virus is a feral mouse retrovirus that causes hind leg
paralysis in laboratory strains of mice [13].
Why endogenous retroviruses?
Why do retroviral loci play a role in autoimmunity? En-
dogenous retroviruses span the divide between self and
foreign. On one hand, they are latently present in all
nucleated cells of the body, and there is no way the im-
mune system can rid the body of them. On the other
hand, they still have the ability, if expressed, to activate
genes and/or to stimulate the innate immune system and
trigger a response like a foreign microorganism. And even
in situations where the viruses are not endogenous but
horizontally transmitted retroviral infections have great
permanence and generally last for life. So we believe
that many forms of human autoimmunity may be influ-
enced by retroviruses. A well-known example is human
Tropical Spastic Paraparesis, which is caused by a
human T-lymphotropic virus, HTLV [14]. However, ret-
roviruses may not be the only agents having this effect.
Other microorganisms establish intimate, long lasting
relationships with the human body, most notably the
bacteria of the gut.
Why sets of retroviral loci in autoimmunity? It seems
that no retroviral locus in the genome is complete in the
human populations for which there are sequences. Of
the approximately 100,000 retroviral sequences only 51
can with zero to two mutations encode a viral protein
[3]. So defined, a few loci encode all three genes, but
zero to two breaks in the reading frame may be present,
and there may also be point mutations. Thus, we think
recombination or complementation between at least two
viruses is necessary for infectious viral particles to form.
Recombination of viral information could take place by
formation of mixed particles containing two different viral
genomes, i.e. during complementation [15]. In successive
steps, information from more than two viral sequences
may be recruited. Thus, we by no means exclude the con-
tribution of more than two loci. However, the present
group-sizes investigated (about a thousand persons or
less) and techniques applied are probably not sufficient to
demonstrate a 3-way synergy between viruses. In Rheuma-
toid Arthritis, we have seen suggestive evidence that three
viruses contribute, but no formal proof. The issue may be
resolved if we obtain sequences of recombined viruses.
Comparison of diseases; Contributions of viruses
Retroviruses, in general, have three genes, gag, pol and
env, and a noncoding region, the LTR, which contains
regulatory elements such as a promoter and an enhancer.
The locus HERV-Fc1 may contribute to recombination or
complementation in MS, RA and MM. In all three situa-
tions, we think the locus could provide the ENV function.
HERV-Fc1 env seems intact (Jensen SB et al, unpublished
observation). Moreover, HERV-Fc1 is a gamma-retrovirus,
and the ENV of these viruses has the advantage that the
surface protein is covalently linked to transmembrane
protein by an S-S bridge [16]. Recruitments of env from
gamma-retroviruses to beta-retroviruses have been seen
before [16]. In contrast, sequence analyses show that
HERV-Fc1 pol is interrupted in several places and that
HERV-Fc1 GAG does not contain the usual processing
sites phe-pro or tyr-pro. In accordance with this, the
HERV-Fc1 GAG polyprotein is not properly processed but
remains a polyprotein when human cells are transfected
with expression systems containing HERV-Fc1 gag and/or
gagpol (Nissen KK, et al., unpublished observation).
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Reverse transcriptase activity was also not detectable in
pelleted supernatants from such cells.
The other locus observed in MS is a HERV-K locus
on chromosome 19. All except three viral loci with in-
tact or near-intact pol regions in the human genome
belong to this family. HERV-Ks are the only candidates
for contributing the POL functions in the four diseases
here. This is important as POL functions, protease, re-
verse transcriptase, and integrase are the main targets
for drug action in antiretroviral therapy. This means
that an attempt at treating autoimmune diseases with anti-
retrovirals could usefully draw on the drug-sensitivities of
HERV-Ks for drug selection. Several papers suggest that
MS is suppressed in HIV patients treated with a cocktail of
antiretrovirals [17–19] but not in untreated HIV [19, 20].
HERV-Ks may further contribute the GAG function in
MS, MM, T1D and possibly RA. However, HERV-H on
chromosome 22 could also contribute the GAG function
in RA. It is presently unclear, which loci could poten-
tially provide the LTRs.
Could increased complexity of the viral interactions
translate into the later debut of the disease? In Type 1
Diabetes we observed the interaction of two similar
viruses. This disease often has a childhood debut. In MS,
we have observed interaction between two dissimilar ret-
roviruses. This disease typically starts in patients in their
twenties or thirties. In Rheumatoid Arthritis, we may see
interaction of 3 dissimilar viruses. This disease typically
unveils at age fifty or sixty. Thus, in this limited material
a tendency is present. It would be most interesting to in-
vestigate a related disease, Juvenile Idiopathic Arthritis,
which typically debuts very early, sometimes at an age of
1 to 2 years. Is this a retrovirally related disease, too, and
if so, how do the virus(es) activate so quickly? Could
these patients carry a complete viral locus?
Theories about MS
There are two contemporary sets of data for genetic
effects in MS: The outcome could be a result of many
minor variations in a multitude of genes [21]. Sawcer
et al. analyzed thousands of DNA from cases and con-
trols recruited in Europe and North America utilizing
Illumina Chips, which analyze hundreds of thousands of
SNPs, and used sophisticated modelling to compensate
for different ethnicity. The authors concluded that in the
order of a hundred genes influence the risk of MS, many
of them genes in the immune system.
Alternatively, MS could be the result of a few drastic
changes (this paper). For several reasons, we favor the
second possibility. There is a lot of slack in biological
systems, and they are able to accommodate small per-
turbations gracefully. Of course, one can invoke chaos
theories, but biological systems, in general, are not cha-
otic, but highly structured. Random molecular processes
occur but unless they affect the genome they do not tend
to produce basic instability. We think a fundamental
change in the system is necessary, for instance by muta-
tion, viral invasion, or pharmaceutic or toxic drugs. This
leads naturally to a few important genes.
On a technical level there is no disagreement. We have
purposely concentrated on retroviral loci. Sawcer et al.
used Illumina chips. These chips were deliberately de-
signed to focus on single-copy coding genes, and have a
scant representation of multi-copy sequences, such as
retroviruses. Thus, Sawcer et al. could easily have over-
looked a retroviral influence. Moreover, they did not
investigate SNPs on the X chromosome, and this left out
HERV-Fc1.
Result-wise, we observed ten to forty-fold higher odds-
ratios than Sawcer et al. did, but they investigated consider-
ably more cases and obtained lower p-values. Both sets of
results could be true. One could, for instance, speculate
that the MS-associated variations in the many immune
genes described in [21] increase the level of surviving
autoimmune cells, and that activated retroviruses transform
one or more of these to proliferating clone(s).
There is a large body of literature describing the pres-
ence of retroviral particles, called MSRV and related to
HERV-W in MS patients (see for instance [22] and quo-
tations thereof ). Unfortunately, these investigators gen-
erally based their research on proving Koch’s postulates
for the MSRV. However, the endogenous retroviruses
are always present in the human body, at least in latent
form, and their presence, therefore, does not signify a
contagious event. More importantly, the definitive Koch
experiment: To isolate the agents and infect humans
with the purified strains to cause disease cannot be
done, as it is unethical. In short, Koch’s postulates can-
not be applied to human endogenous retroviruses. Other
routes, such as the genetic, may be more productive. If
one insists on reconciliation, we study the role of viral
proteins, whereas Perron et al. study the viral RNA.
Conclusions
The results presented here are all fairly new, and much
remains to be investigated. We are particularly looking
forward to other scientific groups making additional
findings or confirming our results.
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